OGD's article in AAPS J may help [Regulatives / Guidelines]

posted by Shuanghe  – Spain, 2014-09-10 13:39 (4309 d 14:43 ago) – Posting: # 13472
Views: 9,756

Hi,

❝ Just few more questions

❝ a) Does one need to match the dissolution rate (At all time points 15, 30, 45, 60 , 90 and 120 min)or end release at 2 hrs will suffice the need???


❝ b) What if my formulation is faster at 15 min and 30 min (let's BE product is relasing 15% in 15 min in 40% alcohol where as Innovator is releasing only 5%, at 30 min release from test is 40% from reference it is 30%) but after 30 min time point release from trest poduct is slower till end.


According to the authors from OGD (published in AAPS J. 2008):
Methods.
The assay was implemented for several MR drug products under review at the Office of Generic Drugs (OGD). The assay
employs USP Apparatus I or II and 900 mL of 0.1 N HCl media containing ethanol (v/v) at: 0%; 5%; 20%; and 40%,
sampling every 15 minutes until 2 hours. Applicants conduct these studies on all drug product strengths.

The dissolution results are categorized as
Case I: If at 2 hours, % dissolved of the generic product in 40% ethanol is ≤ in 0% ethanol, the generic product is considered
robust (does not dose-dump); if not
Case II: at 2 hours, % dissolved of the generic product in ethanol solution is less or comparable to that of the reference, the
potential for dose-dumping is similar for the two products and the generic product is acceptable; if not
Case III: the generic product releases more drug in ethanol than the reference and is unacceptable.


You can download the abstract here

I guess that your is case II.

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
354 visitors (0 registered, 354 guests [including 26 identified bots]).
Forum time: 04:22 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5